{"id":2702,"date":"2019-11-01T12:06:00","date_gmt":"2019-11-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/koronare-herzkrankheit-mit-vorhofflimmern-endgueltiges-aus-fuer-die-antithrombotische-tripel-therapie"},"modified":"2019-11-01T12:06:00","modified_gmt":"2019-11-01T11:06:00","slug":"koronare-herzkrankheit-mit-vorhofflimmern-endgueltiges-aus-fuer-die-antithrombotische-tripel-therapie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2019\/koronare-herzkrankheit-mit-vorhofflimmern-endgueltiges-aus-fuer-die-antithrombotische-tripel-therapie","title":{"rendered":"Koronare Herzkrankheit mit Vorhofflimmern: endg\u00fcltiges Aus f\u00fcr die antithrombotische Tripel-Therapie?"},"content":{"rendered":"<p>Zusammenfassung: Nach den Studien WOEST (mit Vitamin-K-Antagonisten = VKA), PIONEER-AF (mit Rivaroxaban) und RE-DUAL PCI (mit Dabigatran) liegen nun mit AUGUSTUS (mit Apixaban) und ENTRUST-AF (mit Edoxaban) auch f\u00fcr die beiden verbliebenen direkten Antikoagulanzien- (DOAK-) Studien zur antikoagulatorischen Kombinationstherapie vor. Sie belegen die Sicherheit einer dualen Kombinationstherapie von DOAK plus einem P2Y12-Inhibitor (ohne Acetylsalicyls\u00e4ure = [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Nach den Studien WOEST (mit Vitamin-K-Antagonisten = VKA), PIONEER-AF (mit Rivaroxaban) und RE-DUAL PCI (mit Dabigatran) liegen nun mit AUGUSTUS (mit Apixaban) und ENTRUST-AF (mit Edoxaban) auch f\u00fcr die beiden verbliebenen direkten Antikoagulanzien- (DOAK-) Studien zur antikoagulatorischen Kombinationstherapie vor. Sie belegen die Sicherheit einer dualen Kombinationstherapie von DOAK plus einem P2Y12-Inhibitor (ohne Acetylsalicyls\u00e4ure = [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[185,74,684,495,1322,60,1272,77,5312,76,73,1314,1312,2068,5311,71,68,498,65,1328,1327,1033,56,727,2005,4833,181],"class_list":["post-2702","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-acetylsalicylsaeure","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-apixaban","tag-apoplektischer-insult","tag-arteriosklerose","tag-ass","tag-augustus-studie","tag-azetylsalizylsaeure","tag-clopidogrel","tag-direkte-orale-antikoagulanzien","tag-doak","tag-edoxaban","tag-entrust-af-studie","tag-herzinfarkt","tag-hirninfarkt","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-neue-orale-antikoagulanzien","tag-noak","tag-prasugrel","tag-schlaganfall","tag-thrombozytenaggregationshemmer","tag-ticagrelor","tag-tripel-therapie","tag-vorhofflimmern"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2702","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2702"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2702\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2702"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2702"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2702"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}